Cipla Signs Qilu Deal to Launch Pembrolizumab Biosimilar in U.S.

Cipla's agreement with Qilu Pharmaceutical positions the Indian generics major directly in the pembrolizumab biosimilar race, a corridor where US biosimilar approval pathways and interchangeability designations will determine commercial viability as Merck's Keytruda patent estate begins to open.

Under the partnership, Qilu supplies the biosimilar candidate while Cipla holds responsibility for US commercialisation. The arrangement follows a familiar co-development structure in the oncology biosimilar space: a biologics-capable manufacturer paired with a market-access operator holding established regulatory relationships with FDA. Neither party has disclosed the financial terms or the current development stage of the molecule.

For regulatory affairs leads, the filing strategy will be the immediate focal point. Pembrolizumab biosimilar applicants must navigate a reference product with an extensive indication list, meaning extrapolation arguments will require robust comparability data packages aligned with ICH Q5E and FDA's biosimilar guidance framework. Any interchangeability designation sought under 42 U.S.C. § 262(k) adds a further layer of switching-study requirements that will shape both timeline and label scope.

Cipla has been building its biologics infrastructure with declared intent to compete in the US oncology segment. Qilu, a Shandong-based manufacturer, has prior biosimilar development experience and existing GMP-compliant biologics production capacity. The combination addresses a gap Cipla has acknowledged: upstream biologic manufacturing scale that meets 21 CFR Part 600 standards for US market entry.

The pembrolizumab biosimilar field is becoming crowded. Samsung Bioepis, Fresenius Kabi, and several other applicants are at varying stages of FDA review or pre-submission activity, compressing the window for first-mover advantage. Cipla and Qilu's ability to reach a Biologics License Application submission ahead of or concurrent with competitors will be the measurable checkpoint that determines whether this partnership translates into meaningful US market share.

Source: Media4Growth via Indian Pharma Post, 3 September 2026.